US-based Zhittya Genesis Medicine Inc, a company advancing a group of drugs that trigger the human body's natural regeneration process, has received official regulatory approval from COFEPRIS, the Mexican governing body, to test its novel biological drug in patients with Parkinson's disease, it was reported on Tuesday.
Zambrano Hospital in Monterrey, Mexico, will be conducting the phase one clinical study.
Three ascending doses of Zhittya's biological drug will be tested in patients with 'mild' to 'moderately severe' Parkinson's disease. There will be no placebo dose administered in this First in Man proof of concept study. While the primary purpose of this first clinical trial is to test for the safety of the drug, readouts on possible improvements in the patient's Parkinson disease symptoms will also be studied.
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury
Innovent Biologics' Phase 1 anti-CLDN18.2 ADC (IBI343) results published in Nature Medicine
Hemogenyx wins USD120,000 grant to advance scalable CAR-T manufacturing
Varian launches IntelliBlate in Europe, expanding image-guided microwave ablation for cancer care
Otsuka Pharmaceutical acquires Cantargia's CAN10 immunology programme
Biophytis partners with Lynx Analytics to advance AI-driven drug discovery for sarcopenia
MAP Medical agrees distribution deal with Metrix-Secure
Revalesio to reveal RNS60 Phase 3 trial results at SNIS Annual Meeting